Novo Nordisk A/S (NVO) CEO Lars Jorgensen on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 02/02/22
Novo Nordisk Posts Upbeat Q4 Earnings, Expects Obesity Drug Shortages May Soon Be ResolvedBenzinga • 02/02/22
Novo Nordisk's sales increased by 11% in Danish kroner and by 14% at constant exchange rates to DKK 140.8 billion in 2021GlobeNewsWire • 02/02/22
Novo Nordisk Shares Slump As Wegovy Hits US Supply Issues; Deutsche Bank DowngradesBenzinga • 12/20/21
DICERNA INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Dicerna Pharmaceuticals, Inc. - DRNAPRNewsWire • 12/14/21
Digital Behavioral Health Innovator Ksana Health Joins Novo Nordisk's Global Prevention AcceleratorBusiness Wire • 12/09/21
Novo Nordisk announces impact from Volume Based Procurement for insulin in ChinaGlobeNewsWire • 11/26/21
Novo Nordisk Enhances Metabolic Disorder Pipeline With RNAi Drug Maker DicernaSeeking Alpha • 11/19/21
Novo Nordisk strikes $3.3 billion to buy research partner Dicerna PharmaceuticalsMarket Watch • 11/18/21